

Non Alcoholic Steato-Hepatitis Chronic Kidney Disease

A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Trial Status Terminated	Trial Runs In 5 Countries	Trial Identifier NCT04171765 GC41033
-----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 2 Phase
--	-------------------------

NCT04171765 GC41033
Trial Identifiers

Eligibility Criteria:

Gender All	Age >=18 Years & <= 75 Years	Healthy Volunteers No
----------------------	--	---------------------------------
